AKT1 and breast carcinoma: Given the profound dependence of HER2 + breast cancers on PI3K/AKT signaling and the previous reports implicating PI3K activation in trastuzumab/HER2i resistance, we anticipated RAS activation in this context would also serve to reactivate PI3K and promote further dependence upon AKT.